KB Financial Group, Inc. vs McKesson Corporation — how do they compare? KB Financial Group, Inc. trades at $117.53 (market cap $42.79B), while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation is far larger — about 2.4× KB Financial Group, Inc.'s market cap, and KB Financial Group, Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| KB | MCK | |
|---|---|---|
Market Cap | $42.79B | $102.58B |
Sector | Financials | Health |
52-Week High | $124.01 | $995.69 |
52-Week Low | $77.50 | $659.01 |
Dividend Yield | 2.6% | 0.43% |
Enterprise Value | — | $109.12B |
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $124.01, up 2.22% today, with a bullish technical outlook from moving averages and recent momentum. The stock shows strong fundamentals, with net income margin at 27.82% and a P/E ratio of 11.03, indicating potential undervaluation. Recent earnings beats in Q1 and Q2 2026, alongside positive news coverage on diversification efforts, support investor confidence.
The outlook for KB is positive, driven by earnings growth and strategic expansion into non-banking segments. Risks include volatile cash flow trends and high interest expenses. Analyst consensus is mixed but leans hold, with institutional interest steady. Upside potential exists if profitability trends continue, though macroeconomic factors could pressure performance.
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Trailing returns across standard periods
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →